Midazolam Gemepe

Midazolam Gemepe may be available in the countries listed below.

Ingredient matches for Midazolam Gemepe

Midazolam

Midazolam is reported as an ingredient of Midazolam Gemepe in the following countries:

• Argentina

International Drug Name Search

Forfivo XL

Forfivo XL is a brand name of bupropion, approved by the FDA in the following formulation(s):

FORFIVO XL (bupropion hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: INTELGENX CORP
  
  Approval date: November 10, 2011
  
  Strength(s): 450MG ^[RLD]

Has a generic version of Forfivo XL been approved?

No. There is currently no therapeutically equivalent version of Forfivo XL available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Forfivo XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Sustained-release bupropion and bupropion/mecamylamine tablets
  Patent 7,674,479
  Issued: March 9, 2010
  Inventor(s): Zerbe; Horst G. & Paiement; Nadine
  Assignee(s): Intelgenx Corp.
  Sustained-release bupropion hydrochloride pharmaceutical tablets and combination sustained-release bupropion hydrochloride/mecamylamine hydrochloride pharmaceutical tablets are obtained by granulating the bupropion hydrochloride with a hydroxyalkylcelluose, and blending the resulting granules within an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which then is coated, with a means to provide delayed release, such as with an enteric coating composition. The mecamylamine hydrochloride can be contained in a second granule comprising a hydroxyalkylcellulose.
  
  Patent expiration dates:
  
  
  • June 25, 2027
    
    ✓ 
    Drug product
  
  

See also...

• Forfivo XL Consumer Information (Drugs.com)
• Bupropion Consumer Information (Drugs.com)
• Bupropion Consumer Information (Wolters Kluwer)
• Bupropion Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Hydrobromide Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Consumer Information (Cerner Multum)
• Bupropion Advanced Consumer Information (Micromedex)
• Bupropion Hydrochloride AHFS DI Monographs (ASHP)

Adenoscan

See also: Generic Adenocard

Adenoscan is a brand name of adenosine, approved by the FDA in the following formulation(s):

ADENOSCAN (adenosine - injectable; injection)

• 
  Manufacturer: ASTELLAS
  
  Approval date: May 18, 1995
  
  Strength(s): 3MG/ML ^[RLD]

Has a generic version of Adenoscan been approved?

No. There is currently no therapeutically equivalent version of Adenoscan available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Adenoscan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Selective vasodilation by continuous adenosine infusion
  Patent 5,731,296
  Issued: March 24, 1998
  Inventor(s): Sollevi; Alf
  Assignee(s): Item Development AB
  This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL) and in radionucleide scintography.
  
  Patent expiration dates:
  
  
  • March 24, 2015
    
    ✓ 
    Patent use: SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
  
  

See also...

• Adenosine Consumer Information (Wolters Kluwer)
• Adenosine AHFS DI Monographs (ASHP)

Trinordiol

Trinordiol may be available in the countries listed below.

Ingredient matches for Trinordiol

Delapril

Delapril is reported as an ingredient of Trinordiol in the following countries:

• Spain

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Trinordiol in the following countries:

• Austria


• Belgium


• Czech Republic


• Denmark


• France


• Hungary


• Malta


• Netherlands


• Oman


• Portugal


• Slovakia


• Venezuela

Levonorgestrel

Levonorgestrel is reported as an ingredient of Trinordiol in the following countries:

• Austria


• Belgium


• Czech Republic


• Denmark


• France


• Hungary


• Malta


• Netherlands


• Oman


• Portugal


• Slovakia


• Venezuela

International Drug Name Search

Oracea

Oracea is a brand name of doxycycline, approved by the FDA in the following formulation(s):

ORACEA (doxycycline - capsule; oral)

• 
  Manufacturer: GALDERMA LABS LP
  
  Approval date: May 26, 2006
  
  Strength(s): 40MG ^[RLD][AB]

Has a generic version of Oracea been approved?

A generic version of Oracea has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Oracea and have been approved by the FDA:

doxycycline capsule; oral

• 
  Manufacturer: MYLAN
  
  Approval date: July 1, 2010
  
  Strength(s): 40MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oracea. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
  Patent 5,789,395
  Issued: August 4, 1998
  Inventor(s): Amin; Ashok R. & Abramson; Steven B. & Golub; Lorne M. & Ramamurthy; Nungavaram S. & McNamara; Thomas F. & Greenwald; Robert A. & Trachtman; Howard
  Assignee(s): The Research Foundation of State University of New York
  Hospital for Joint Diseases
  A method is disclosed for inhibiting endogenous production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo mammalian system. The method employs a tetracycline compound to inhibit production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the mammalian system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
  
  Patent expiration dates:
  
  
  • August 30, 2016
    
    ✓ 
    Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
  
  



• 
  Method for inhibiting expression of inducible nitric oxide synthase with tetracycline
  Patent 5,919,775
  Issued: July 6, 1999
  Inventor(s): Amin; Ashok R. & Abramson; Steven B. & Golub; Lorne M. & Ramamurthy; Nungavaram S. & McNamara; Thomas F. & Greenwald; Robert A. & Trachtman; Howard
  Assignee(s): The Research Foundation of The State University of New York
  Hospital For Joint Diseases
  The invention is a method of inhibiting the production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo biological system. The method employs a tetracycline compound to inhibit the production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the biological system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
  
  Patent expiration dates:
  
  
  • August 30, 2016
    
    ✓ 
    Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
  
  



• 
  Methods of treating acne
  Patent 7,211,267
  Issued: May 1, 2007
  Inventor(s): Ashley; Robert A.
  Assignee(s): CollaGenex Pharmaceuticals, Inc.
  A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
  
  Patent expiration dates:
  
  
  • April 5, 2022
    
    ✓ 
    Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
  
  



• 
  Methods of treating rosacea
  Patent 7,232,572
  Issued: June 19, 2007
  Inventor(s): Ashley; Robert A.
  Assignee(s): CollaGenex Pharmaceuticals, Inc.
  A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.
  
  Patent expiration dates:
  
  
  • April 5, 2022
    
    ✓ 
    Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
  
  



• 
  Once daily formulations of tetracyclines
  Patent 7,749,532
  Issued: July 6, 2010
  Inventor(s): Chang; Rong-Kun & Raoufinia; Arash & Shah; Niraj
  Assignee(s): Supernus Pharmaceuticals, Inc.
  Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
  
  Patent expiration dates:
  
  
  • December 19, 2027
    
    ✓ 
    Patent use: TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
    ✓ 
    Drug product
  
  

See also...

• Oracea Consumer Information (Drugs.com)
• Oracea Consumer Information (Cerner Multum)
• Oracea Advanced Consumer Information (Micromedex)
• Oracea AHFS DI Monographs (ASHP)
• Doxycycline Consumer Information (Drugs.com)
• Doxycycline Consumer Information (Wolters Kluwer)
• Doxycycline Capsules Consumer Information (Wolters Kluwer)
• Doxycycline Hyclate Consumer Information (Wolters Kluwer)
• Doxycycline Hyclate Delayed-Release Capsules Consumer Information (Wolters Kluwer)
• Doxycycline Hyclate Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Doxycycline Kit Consumer Information (Wolters Kluwer)
• Doxycycline Monohydrate Consumer Information (Wolters Kluwer)
• Doxycycline Suspension Consumer Information (Wolters Kluwer)
• Doxycycline Syrup Consumer Information (Wolters Kluwer)
• Doxycycline Tablets Consumer Information (Wolters Kluwer)
• Doxycycline with Cleanser Consumer Information (Wolters Kluwer)
• Doxycycline Consumer Information (Cerner Multum)
• Adoxa Pak Advanced Consumer Information (Micromedex)
• Atridox Advanced Consumer Information (Micromedex)
• Vibramycin Hyclate Advanced Consumer Information (Micromedex)
• Doxycycline Advanced Consumer Information (Micromedex)
• Doxycycline Subgingival Advanced Consumer Information (Micromedex)
• Doxycycline AHFS DI Monographs (ASHP)
• Doxycycline Calcium AHFS DI Monographs (ASHP)
• Doxycycline Hyclate AHFS DI Monographs (ASHP)
• Doxycycline Hyclate eent AHFS DI Monographs (ASHP)
• Doxycycline Monohydrate AHFS DI Monographs (ASHP)

Cefixim-100 XL Lab

Cefixim-100 XL Lab may be available in the countries listed below.

Ingredient matches for Cefixim-100 XL Lab

Cefixime

Cefixime is reported as an ingredient of Cefixim-100 XL Lab in the following countries:

• Vietnam

International Drug Name Search

Buto Air

Buto Air may be available in the countries listed below.

Ingredient matches for Buto Air

Salbutamol

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Buto Air in the following countries:

• Spain

International Drug Name Search

Amlodipin Orion

Amlodipin Orion may be available in the countries listed below.

Ingredient matches for Amlodipin Orion

Amlodipine

Amlodipine maleate (a derivative of Amlodipine) is reported as an ingredient of Amlodipin Orion in the following countries:

• Finland

International Drug Name Search

Edaravone

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0000089-25-8

Chemical Formula

C10-H10-N2-O

Molecular Weight

174

Therapeutic Category

Free oxygen radical scavenger

Chemical Name

3-methyl-1-phenyl-2-pyrazolin-5-one (WHO)

Foreign Names

• Edaravonum (Latin)
• Edaravon (German)
• Édaravone (French)
• Edaravona (Spanish)

Generic Names

• Edaravone (OS: JAN)
• BRN 0609575 (IS)
• MCI-186 (IS)
• Norphenazone (IS)
• UNII-S798V6YJRP (IS)

Brand Name

• Radicut
  Tanabe Mitsubishi, Japan

International Drug Name Search

Glossary

IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.